Tecan Group AG
SIX:TECN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
197.5
373.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Tecan Group AG
Tecan Group AG
Cost of Revenue
Tecan Group AG
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tecan Group AG
SIX:TECN
|
Cost of Revenue
-CHf653.3m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Bachem Holding AG
SIX:BANB
|
Cost of Revenue
-CHf398.4m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-13%
|
|
|
Siegfried Holding AG
SIX:SFZN
|
Cost of Revenue
-CHf952.1m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Lonza Group AG
SIX:LONN
|
Cost of Revenue
-CHf4.7B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-6%
|
|
|
PolyPeptide Group AG
SIX:PPGN
|
Cost of Revenue
-€315.6m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
SKAN Group AG
SIX:SKAN
|
Cost of Revenue
-CHf79.5m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-456%
|
CAGR 10-Years
N/A
|
|
Tecan Group AG
Glance View
Nestled in the heart of Switzerland lies Tecan Group AG, a company that has been quietly revolutionizing the laboratory world. Founded in 1980, Tecan has transformed itself from a small enterprise into a powerhouse in the life sciences and diagnostics sectors. The company's journey is one of precision and innovation, as it specializes in the development, production, and distribution of sophisticated laboratory instruments and solutions. These solutions are not merely products; they are the linchpins of automation that help streamline research, diagnostics, and the pharmaceutical sectors. Tecan's knack for integrating complex biochemical processes into accessible technology has proven critical for laboratories seeking speed and accuracy in processes like sample handling, testing, and data management. Tecan's business model thrives on a multifaceted approach. It sells its high-tech instruments and consumables directly to a diverse client base, including pharmaceutical companies, biotechnology firms, and research institutions. Beyond selling physical products, Tecan also benefits from providing value-added services such as after-sales support and bespoke system adaptations, ensuring that its clients can optimize their workflows. By combining cutting-edge technology with customer-centric service offerings, Tecan ensures recurring revenue streams. Its strategic prowess in securing long-term partnerships with leading institutions further cements its stance as not just a vendor, but a reliable partner in scientific discovery and healthcare advancement.
See Also
What is Tecan Group AG's Cost of Revenue?
Cost of Revenue
-653.3m
CHF
Based on the financial report for Jun 30, 2024, Tecan Group AG's Cost of Revenue amounts to -653.3m CHF.
What is Tecan Group AG's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-15%
Over the last year, the Cost of Revenue growth was 6%. The average annual Cost of Revenue growth rates for Tecan Group AG have been -14% over the past three years , -15% over the past five years .
You don't have any saved screeners yet